In the first half of 2025, Aurisco's operating revenue was 822 million yuan, a year-on-year increase of 12.50%

Aurisco Pharmaceutical Co., Ltd. released the summary of its semi-annual report for 2025. The report shows that at the end of the reporting period, total assets were 3.903 billion yuan, an increase of 0.65% compared to the end of the previous year; net assets attributable to shareholders of the listed company were 2.429 billion yuan, an increase of 4.19% year-on-year. Operating income for the reporting period was 822 million yuan, an increase of 12.50% year-on-year; total profit was 268 million yuan, an increase of 23.66% year-on-year; net profit attributable to shareholders of the listed company was 235 million yuan, an increase of 24.55% year-on-year. The net cash flow generated from operating activities was 215 million yuan, an increase of 28.71% year-on-year. Among the top 10 shareholders, Zhejiang Tongben Investment Co., Ltd. and Chu Yizhou held shares at 37.81% and 27.65%, respectively